东诚药业：钇90项目正在进行临床前相关项目的整理工作

Core Viewpoint - The company is actively engaged in the development of Yttrium-90 (Y-90) radiopharmaceuticals and is currently organizing preclinical projects related to this initiative [1] Group 1 - The company has received inquiries from investors regarding its layout in the Yttrium-90 radiopharmaceutical treatment field [1] - The company confirmed that it is in the process of organizing relevant preclinical projects for the Y-90 initiative [1]